This report provides a comprehensive overview of the size of the SARS-CoV-2 COVID Vaccine market, segmentation of the industry (by geography and vaccine technology), key players and the vast potential of vaccines that are in clinical trials. Kelly Scientific analysis indicates that the global COVID vaccine market was worth $59 billion in 2021. However, our forecast indicates that an initial drop will occur in 2022 due to a number of factors including single booster shots as opposed to two shot vaccines and reduced prices in vaccines due to competition.
The COVID vaccine industry is expected to then grow significantly at a CAGR of over 9% and reach $47.5 billion by 2026. This is due to an opening up of the market from a closed government dominated space to one in which private healthcare providers and companies can purchase vaccines. There will also be a continued significant un-met need for vaccine boosters in an endemic situation.

This report describes the evolution of such a huge market in 8 chapters supported by over 74 tables and figures in over 137 pages. The report focuses on the following:

• An overview of the SARS-CoV2 virus that includes: genetic and structural analysis, mutation and variant characterization
• Global COVID vaccine market, global landscape analysis, vaccine technology breakdown and leading market players
• Advance purchase agreements, marketed/pipeline products, financial analysis and business strategy of the major companies in this space
• Focus on current trends, business environment, pipeline products, clinical trials, and future market forecast for COVID vaccines to 2026
• Clinical trial timelines for major vaccines in the pipeline
• Insight into the challenges faced by stakeholders, particularly manufacturers and governments
• Insight into the emergence of variants and their impact on vaccine effectiveness and the overall market
• Financial market forecast through 2026 with CAGR values of all market segments – vaccine technology, geography (US, EU, UK, Japan, RoW) and major players
• Influence of the molecular diagnostics, PCR testing and POC testing landscapes
• Numbers of vaccine doses available by each manufacturer per annum
• Geographical analysis and challenges within countries with respect to advance purchase agreements and distribution channels